Oncotelic Therapeutics Inc OTLC

Healthcare Biotechnology

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. The Company has eight primary drug and AI technology programs: AL-101, an intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P, a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503, a second generation VDA for the treatment of liquid tumors with focus on childhood leukemia; OT-101, an antisense against TGF-ß2 for the treatment of various cancers and viruses, including SARS and the COVID-19, and Artemisini, a natural derivative from an Asian herb Artemisia Annua that inhibits the ability of various viruses to multiply.

OTCQB:OTLC - Post by User

Oncotelic Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by DepartedSe7enon Oct 22, 2021 8:28pm

53 Views

Post# 34039871

ONCOTELIC ANNOUNCES UPDATE ON THE OT-101 CLINICAL PROGRAMS

ONCOTELIC ANNOUNCES UPDATE ON THE OT-101 CLINICAL PROGRAMS INCLUDING C001 COVID STUDY:
https://oncotelic.irpass.com/ONCOTELIC-ANNOUNCES-UPDATE-ON-THE-OT-101-CLINICAL-PROGRAMS-INCLUDING-C001-COVID-STUDY-10-20-2021

<< Previous

Bullboard Posts

Next >>

New tech for Canadian drone developer to boost emergency response